OCUL | Ticker Profile - Titan Protect

OCUL

Ocular Therapeutix, Inc.

Healthcare · Biotechnology · NGM

$8.25

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.9B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.59

Based on estimated future earnings — lower means cheaper

Rev Growth

+0.8%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-68.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$27.00

+227% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 11 analysts covering this stock

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

https://www.ocutx.com

Country: United States Employees: 325 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.663

Good returns relative to risk taken

Kelly Fraction

0.0432

Modest edge detected — smaller position warranted

Calmar Ratio

0.437

Drawdown risk outweighs the returns — higher risk profile

Annual Return

25.0%

Historical annualised return based on price data

Max Drawdown

-57.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.93

Less volatile than the market — more defensive

52W High

$16.44

50% below the year high

52W Low

$6.23

32% above the year low

Avg Volume

3,766,422

Average daily shares traded — higher means easier to buy and sell

Short Ratio

8.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

13.4%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.44

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

13.66

Heavy leverage — higher financial risk if revenues decline

Current Ratio

14.81

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

14.49

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-865.5%

Profit from core operations before interest and tax

Free Cash Flow

$-148,761,504

Negative — the business is spending more than it generates

Revenue (TTM)

$52M

Total revenue over the last 12 months

Net Income

$-290,497,984

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$34.00

Target Median

$27.00

Target Low

$18.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go